Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.71 |
| ▸ | CNR1 | P21554 | 6/20 | 0.71 |
| ▸ | PPARA | Q07869 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4891604 | 1.00 | CNR2 (0.71) | CNR2CNR1PPARA | |
| SCHEMBL4250869 | 0.88 | CNR1 (0.91) | CNR2CNR1PPARA | |
| SCHEMBL4892010 | 0.86 | CNR1 (0.60) | CNR2CNR1 | |
| SCHEMBL4892373 | 0.86 | CNR1 (0.60) | CNR2CNR1 | |
| SCHEMBL4613345 | 0.85 | CNR1 (0.61) | CNR2CNR1 | |
| SCHEMBL4613351 | 0.85 | CNR1 (0.61) | CNR2CNR1 | |
| SCHEMBL4613349 | 0.85 | CNR1 (0.61) | CNR2CNR1 | |
| SCHEMBL4611298 | 0.84 | CNR2 (0.59) | CNR2CNR1 | |
| SCHEMBL4613451 | 0.84 | CNR2 (0.59) | CNR2CNR1 | |
| SCHEMBL4613448 | 0.84 | CNR2 (0.59) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287517-A1 | Pyrazole Derivatives as Cb1 Modulators | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287517-A1 | Pyrazole Derivatives as Cb1 Modulators | CNR1, CNR2, HTR3C | CNR2 2/4885CNR1 1/4885PPARA 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.